The Hormonal Contraceptives Market size was valued at USD 16.77 billion in 2024 and is expected to reach USD 23.75 billion by 2032, growing at a CAGR of 4.49% over the forecast period of 2025-2032.
The global hormonal contraceptives market has been growing steadily, fueled by increasing awareness towards reproductive health, improving female workforce participation, and support from government services toward family planning. The adoption is being propelled by advancements in delivery methods low-dose patches, implants, hormone-free alternatives, etc.
The U.S. Hormonal Contraceptives Market size was valued at USD 6.75 billion in 2024 and is expected to reach USD 9.24 billion by 2032, growing at a CAGR of 4.03% over the forecast period of 2025-2032. The North American hormonal contraceptives market is dominated by the U.S. owing to high awareness regarding reproductive health, easy access to insurance, and access to health services. Its dominance is further justified by the key pharmaceutical firms afoot with constant innovation in the birth control methods.
Drivers
Increasing Awareness of Family Planning is Driving the Market Growth
There has been a notable increase in awareness programs and health campaigns that educate the population about reproductive health and family planning in the past few years. This experience provides insights to women and couples for understanding the advantage of spacing/limiting pregnancies through contraception, thereby helping to improve maternal and child health indicators. The global rise of hormone-based contraceptives can be attributed to improved media, healthcare providers, and community program access to information, giving women the power to choose their contraception.
An estimated 82% of women aged 18-49 in the U.S. used a contraceptive method in the past 12 months, and oral contraceptives are one of the most widely used contraceptive methods.
Almost 39% of women of reproductive age said they had seen social media posts about birth control in the past year, showing how family planning has remained more front-of-mind, as well.
Technological advancements in contraceptive methods are fuelling the market growth.
Hormonal contraceptives have been made safer, more convenient, and more effective through technological innovation. Alternative delivery methods, including low-dose patches, long-acting implants, rings, and non-hormonal methods, have minimized adverse effects and improved adherence. These innovations appeal to different preferences and lifestyles and should make contraception palatable and available to a wider population. Ongoing R&D improves formulators with lesser hormonal doses integrated into affected individuals, lowers its health hazard, and further attracts additional users. This continuous innovation is largely driving the market growth.
Australia's Therapeutic Goods Administration has approved the use of the Mirena intrauterine device up to eight years, following evidence that the device is effective beyond the initial five-year window.
Adam works as a non-hormonal male contraceptive implant and has already been proven to effectively work for at least two years in clinical trials. The implant is reversible, making it a viable substitute for traditional (male) contraceptives.
Restraint
Side Effects and Health Concerns are Restraining the Market from Growing.
The hormonal contraceptives market is also challenged by the side effects and health risks associated with the usage of hormonal contraception, which is among the primary factors affecting the growth of the hormonal contraceptives market. Hormonal contraceptives (such as pills, patches, and implants) can have side effects that include nausea, headaches, weight gain, mood swings, and irregular bleeding. Other serious but rarer risks include thrombosis, hypertension, cardiovascular issues, and stroke, particularly in women who smoke or those who have underlying medical issues. Because of these potential negative side effects, some women are reluctant to begin or continue hormonal contraception. Other users look for other non-hormonal alternatives as they are worried about the long-term safety, which also restricts significant market uptake. Hormonal contraceptives, while safe and effective, require a detailed history to assess risk factors, sometimes even contraindications, which may slow the uptake of contraception.
By Product
The pills segment dominated the hormonal contraceptives market in 2024 with a 48.7% market share. Due to its longer standing, extensive availability, and convenience in usage, Oral contraceptive pills are the first choice in a general practice; some even have high awareness and acceptance of these in reproductive-aged women. Both retail and hospital pharmacy accessibility, coupled with demand-side coverage offered by health insurance in developed regions, all contribute to a further increase in adoption. Pills have the leading share in the market, as their varying combinations and dosing options also allow for a broad range of user types.
The fastest growing segment during the forecast period is anticipated to be hormonal implants due to the long-lasting effects of the product, which have minimal user intervention and maximal compliance. While the daily pill necessitates regular monitoring, the implants offer easily installed, multi-year contraception, making them perfect for women searching for a low-maintenance and highly effective contraceptive. An increase in public health campaigns supporting adoption of the technology, increasing availability in emerging markets, and recommendations from global health organizations are increasing their adoption. The hormonal implant is anticipated to experience the most growth as awareness increases and access expands in low–and middle-income countries.
By Contraceptive Hormone
The combined hormone contraceptives segment led the hormonal contraceptives market in 2024 with a 74.56% market share, owing to their wide clinical acceptability, double hormonal effect, and broad application of different delivery forms such as pills, patches, and vaginal ring. These contraceptives are combination pills (estrogen + progestin) and provide excellent cycle control and relief of many menstrual-associated symptoms, features which many users of the pill find highly desirable. This segment also accounts for the bulk of the market, due to the availability of a large number of branded and generic segments, patient and physician preference, as well as long-term familiarity with the product type, particularly in developed markets such as North America and Western Europe with high access to healthcare facilities.
Progestin-Only segment anticipated to register the fastest growth during the forecast period, owing to rising preference for estrogen-free alternatives among women unable to tolerate estrogen, as well as those who also have associated health risks such as high blood pressure or past incidence of blood clots. Progestin-only birth control—pills, injections, and implants—are another option, as they are also favored while breastfeeding and for women looking for long-term, low-maintenance birth control. Global growth for this segment continues to be further propelled by expanding clinical recommendations, more widespread product availability, and increased uptake in lower-resource settings.
In March 2024, the US FDA greenlit over-the-counter sales of the progestin-only pill called Opill, in a landmark move for contraceptive availability.
By Distribution Channel
The hormonal contraceptives market was dominated by the hospital pharmacies segment in 2024, with a 79.02% market share due to the authenticity of hospital-based prescribing and dispensing for first-time users, along with long-acting reversible contraceptives such as implants and IUDs. Family planning services are often provided at hospitals, which can be a first point of care for diagnosis, counselling, and prescription. Moreover, in many countries, contraceptives are subsidized or covered 100% in a hospital setting within the framework of the public health scheme, which also increases the availability of the methods and increases adherence in patients who have been prescribed a method.
The retail pharmacies segment is expected to be the fastest growing during the forecast period due to the promise of increased convenience, wider over-the-counter (OTC) availability in some areas, and growing use of telemedicine and online pharmacy services. With the increased knowledge of all forms of contraception, along with reduced stigma regarding the purchasing of birth control, women are utilizing a retail pharmacy to obtain pills, patches, and emergency contraceptives in a timely fashion. This distribution channel is rapidly growing, driven by the major expansion of pharmacy networks in both urban and semi-urban areas, coupled with supporting regulations for easier access.
North America dominated the hormonal contraceptives market with a 44.6% market share due to high awareness and knowledge regarding reproductive health, and well-established healthcare infrastructure, and many options available in the market. The provision of government-funded programs, insurance reimbursement policies, and access to different types of hormonal contraceptives available through hospital and retail pharmacies are major factors contributing to the region leading the charge. In addition, the presence of established pharmaceutical companies and frequent product innovation (e.g., low-dose and long-acting reversible contraceptives) continues to strengthen North America as the major region in the global contraceptive market.
The hormonal contraceptives market in Asia Pacific is anticipated to grow at the fastest rate, due to the high geriatric population in the region, the greater demand for parenting decision-making, improved disposability of suburban living and increasing family income, and growing urbanization. The economic development of countries, such as India and China, wherever directly contributed to the easy availability of health care facilities and contraceptive products. In addition, conducive government initiatives, increasing healthcare infrastructure are boosting adoption rates by NGOs for reproductive health. In addition, changing cultural attitudes towards contraception, coupled with more affordable generic options, are providing significant market growth opportunities for the region.
The hormonal contraceptives market is growing significantly in Europe due to the affordable healthcare policy, growing awareness towards reproductive health, and rising demand for modern contraceptive methods. Governments are implementing initiatives to improve contraceptive access. For instance, in January 2023, a law was passed in Luxembourg to make the contraceptive pill, as well as all other methods of hormonal contraception - such as patches and vaginal rings - free of charge up to the age of 25 and reimbursed by the National Health Fund (CNS). Also, the adoption rates and governmental support for family planning plans in the various European countries, including Germany, France, and the United Kingdom, are pushing the growth.
Technology advances, with higher research and development investment, are also driving the growth of the market. Bayer has announced the opening of a new manufacturing facility in Finland to increase production capacity for long-acting reversible contraceptives (LARCs) that include hormonal IUDs and implants, for which it recently invested USD 267.5 million (Euro 250 million) in September 2023 Additionally, the increasing incidence of STDs and unplanned pregnancies in the region drives the demand for contraceptives, which in turn is propelling the market growth.
Latin America has moderate growth in the hormonal contraceptives market, as Latin America is undergoing an increasing awareness related to family planning, increasing adoption of family planning, and changing perception regarding contraception practices. In addition, the market is growing due to government initiatives to promote reproductive health and increasing cases of sexually transmitted infections (STIs). The key challenge is due to the cultural and societal barriers, fear of side effects, and expense of the neural implant at the initial development stage, and also the unavailability of local healthcare services in rural areas.
The hormonal contraceptives market in the Middle East and Africa (MEA) is also exhibiting moderate growth. The market is being accelerated by the growing awareness about family planning, governments promoting contraception, and a developing healthcare infrastructure. Nevertheless, cultural and /or religious customs, as well as limited access to health and medical services in some regions, can be barriers to market development.
Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Organon & Co., Mylan N.V. (Viatris Inc.), Allergan (AbbVie Inc.), Johnson & Johnson Services Inc., Gedeon Richter Plc, Afaxys Inc., Cipla Limited, and other players.
May 2025 – A global health care company reported encouraging results of its Phase 3 clinical trial evaluating the contraceptive safety and efficacy of its investigational product, XULANE LO. The once-weekly, low-dose dermal patch provides 150 mcg of norelgestromin and 17.5 mcg of ethinyl estradiol per day and is intended for women of childbearing age. The findings affirm the product's potential to be both safe and effective as a hormonal contraceptive option.
February 2024 – Bayer announced a strategic partnership with US-based biotechnology company Daré Bioscience to develop a new, hormone-free monthly contraceptive. The product, a vaginal ring, provides up to three weeks of pregnancy protection without any user action during sex. This alliance is set to increase the array of contraception for women by adding a non-hormonal option.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 16.77 Billion |
| Market Size by 2032 | USD 23.75 Billion |
| CAGR | CAGR of 4.49% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Pills, Skin Patches, Intrauterine Devices, Hormonal Implants, Vaginal Rings, Others) • By Contraceptive Hormone (Progestin Only, Combined Hormone Contraceptives) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Organon & Co., Mylan N.V. (Viatris Inc.), Allergan (AbbVie Inc.), Johnson & Johnson Services Inc., Gedeon Richter Plc, Afaxys Inc., Cipla Limited, and other players. |
Ans: The Hormonal Contraceptives Market is expected to grow at a CAGR of 4.49% from 2025 to 2032.
Ans: The Hormonal Contraceptives Market was USD 16.77 billion in 2024 and is expected to reach USD 23.75 billion by 2032.
Ans: Increasing awareness of family planning is driving the market growth.
Ans: The “Combined Hormone Contraceptives” segment dominated the Hormonal Contraceptives Market.
Ans: North America dominated the Hormonal Contraceptives Market in 2024.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Usage Rate and Adoption Trends (2024)
5.2 Product-wise Market Share and Growth Trends (2024)
5.3 Regional Demand Analysis (2020–2032)
5.4 Government and NGO Contraceptive Program Reach (2024)
5.5 Healthcare Spending on Hormonal Contraceptives (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Hormonal Contraceptives Market Segmentation By Product
7.1 Chapter Overview
7.2 Pills
7.2.1 Pills Market Trends Analysis (2021-2032)
7.2.2 Pills Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Skin Patches
7.3.1 Skin Patches Market Trends Analysis (2021-2032)
7.3.2 Skin Patches Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Intrauterine Devices
7.4.1 Intrauterine Devices Market Trends Analysis (2021-2032)
7.4.2 Intrauterine Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Hormonal Implants
7.5.1 Hormonal Implants Market Trends Analysis (2021-2032)
7.5.2 Hormonal Implants Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Vaginal Rings
7.6.1 Vaginal Rings Market Trends Analysis (2021-2032)
7.6.2 Vaginal Rings Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Others
7.7.1 Others Market Trends Analysis (2021-2032)
7.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Hormonal Contraceptives Market Segmentation By Contraceptive Hormone
8.1 Chapter Overview
8.2 Progestin Only
8.2.1 Progestin Only Market Trend Analysis (2021-2032)
8.2.2 Progestin Only Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Combined Hormone Contraceptives
8.3.1 Combined Hormone Contraceptives Market Trends Analysis (2021-2032)
8.3.2 Combined Hormone Contraceptives Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Hormonal Contraceptives Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Other Pharmacies
9.4.1 Other Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Other Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Hormonal Contraceptives Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.4 North America Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.2.5 North America Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.6.2 USA Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.2.6.3 USA Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.7.2 Canada Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.2.7.3 Canada Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.8.2 Mexico Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.2.8.3 Mexico Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Hormonal Contraceptives Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.4 Europe Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.5 Europe Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.6.2 Germany Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.6.3 Germany Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.7.2 France Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.7.3 France Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.8.2 UK Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.8.3 UK Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.9.2 Italy Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.9.3 Italy Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.10.2 Spain Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.10.3 Spain Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.11.2 Poland Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.11.3 Poland Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.12.2 Turkey Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.12.3 Turkey Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.4 Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.5 Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.6.2 China Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.6.3 China Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.7.2 India Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.7.3 India Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.8.2 Japan Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.8.3 Japan Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.9.2 South Korea Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.9.3 South Korea Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.10.2 Singapore Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.10.3 Singapore Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.11.2 Australia Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.11.3 Australia Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Hormonal Contraceptives Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.6.2 UAE Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.5.6.3 UAE Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.8.2 Qatar Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.5.8.3 Qatar Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.9.2 South Africa Hormonal Contraceptives Market Estimates and Forecasts by Contraceptive Hormone (2021-2032) (USD Billion)
10.5.9.3 South Africa Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.4 Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.6.5 Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.6.2 Brazil Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.6.6.3 Brazil Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.7.2 Argentina Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.6.7.3 Argentina Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Contraceptive Hormone (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Hormonal Contraceptives Market Estimates and Forecasts, by Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 Bayer AG
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2, Pfizer Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Teva Pharmaceutical Industries Ltd.,
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Organon & Co.,
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Mylan N.V. (Viatris Inc.)
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Allergan (AbbVie Inc.),
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Johnson & Johnson Services Inc.,
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Gedeon Richter Plc
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Afaxys Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Cipla Limited
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product
By Contraceptive Hormone
By Distribution Channel
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/sample-request/3063
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: https://www.snsinsider.com/sample-request/3063
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report: